Abstract:Lecithin:cholesterol acyltransferase (LCAT) exhibits α-activity on high-density and β-activity on low-density lipoproteins. However, the molecular determinants governing LCAT activation by different apolipoproteins remain elusive. Uncovering these determinants would offer the opportunity to design and explore advanced therapies against dyslipidemias. Here, we have conducted coarse-grained and all-atom molecular dynamics simulations of LCAT with nanodiscs made with α-helical amphiphilic peptides either derived from apolipoproteins A1 and E (apoA1 and apoE) or apoA1 mimetic peptide 22A that was optimized to activate LCAT. This study aims to explore what drives the binding of peptides to our previously identified interaction site in LCAT. We hypothesized that this approach could be used to screen for binding sites of LCAT in different apolipoproteins and would provide insights to differently localized LCAT activities. Our screening approach was able to discriminate apoA1 helixes 4, 6, and 7 as key contributors to the interaction with LCAT supporting the previous research data. The simulations provided detailed molecular determinants driving the interaction with LCAT: the formation of hydrogen bonds or salt bridges between peptides E4 or D4 and LCAT S236 or K238 residues. Additionally, salt bridging between R7 and D73 was observed, depending on the availability of R7. Expanding our investigation to diverse plasma proteins, we detected novel LCAT binding helixes in apoL1, apoB100, and serum amyloid A. Our findings suggest that the same binding determinants, involving E4 or D4 -S236 and R7-D73 interactions, influence LCAT β-activity on low-density lipoproteins, where apoE and or apoB100 are hypothesized to interact with LCAT. Atherosclerotic cardiovascular disease is caused by the accumulation of cholesterol in arteries. A developing class of therapies against it attempt to promote the efficiency of high-density lipoprotein (HDL), which removes cholesterol from peripheral cells. Importantly, this includes cholesterol-laden macrophages, also known as foam cells, present in atherosclerotic lesions. In this context, one strategy focuses on improving the cholesterol carrying capacity of HDL by improving the enzymatic activity of lecithin:cholesterol acyltransferase (LCAT). Although LCAT remodels HDL to accept more cholesterol, it also remodels low-density lipoprotein (LDL), which has an opposite effect to HDL. In other words, LDL brings cholesterol to peripheral cells. We hypothesize that this may be part of the reason why LCAT activation hasn't shown clinical success thus far. In order to investigate this, we must selectively inhibit LCAT's activity on LDL, which in turn requires us to know which amino acids take part in the LCAT-HDL and LCAT-LDL interactions. In this article, we've used molecular dynamics simulations to reveal these amino acids. This information will be useful in the optimization of LCAT and HDL based therapies against atherosclerosis as well as in the design of HDL-like drug delivery systems whose properties are affected by LCAT.

Computational and experimental investigations of a novel aptamer targeting oxidized low-density lipoprotein

Rapid Identification Of Specific Dna Aptamers Precisely Targeting Cd33 Positive Leukemia Cells Through A Paired Cell-Based Approach

In Silico Design and Validation of High-Affinity RNA Aptamers Targeting Epithelial Cellular Adhesion Molecule Dimers

Cross-linking modifications of HDL apoproteins by oxidized phospholipids: structural characterization, in vivo detection, and functional implications

Targeting PCSK9 as a key player in lipid metabolism: exploiting the therapeutic and biosensing potential of aptamers

Development Of New Enzyme-Linked Immunosorbent Assay For Oxidized Lipoprotein(A) By Using Purified Human Oxidized Lipoprotein(A) Autoantibodies As Capture Antibody

Association of oxidized ApoB and oxidized ApoA-I with high-risk coronary plaque features in cardiovascular disease

Dynamic AFM detection of the oxidation-induced changes in size, stiffness, and stickiness of low-density lipoprotein

Abstract 53: An Abundant Dysfunctional Apolipoprotein A1 in Human Atheroma

A label-free electrochemical aptasensor for low-density lipoprotein detection using MoS 2 -Au-Fc nanosheets as a high-performance redox indicator

Selective Molecular Recognition of Low Density Lipoprotein Based on β-Cyclodextrin Coated Electrochemical Biosensor

Systematic evaluation of lecithin:Cholesterol acyltransferase binding sites in apolipoproteins via peptide based nanodiscs: Regulatory role of charged residues at positions 4 and 7

Truncations and in silico Docking to Enhance the Analytical Response of Aptamer-Based Biosensors

Screening and characterization of aptamers for recombinant human programmed death-1 and recombinant extracellular domain of human programmed death ligand-1

Correlation of antiphospholipid antibody recognition with the structure of synthetic oxidized phospholipids. Importance of Schiff base formation and aldol condensation

Selective Anti-melanoma Effect of Phosphothioated Aptamer Encapsulated by Neutral Cytidinyl/Cationic Lipids

Convenient Construction of Orthogonal Dual Aptamer-Based Plasmonic Immunosandwich Assay for Probing Protein Disease Markers in Complex Samples and Living Animals

Biodegradable synthetic high-density lipoprotein nanoparticles for atherosclerosis

Aptamer and sodium alginate decorated graphene oxide composite material with ion responsiveness for Low-density lipoprotein trapping

Advances in the Development of Aptamer Drug Conjugates for Targeted Drug Delivery.

A novel assay to measure low-density lipoproteins binding to proteoglycans